Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

Pathogenesis of Hypertension: A Review

Haralambos Gavras
Published in : Journal of Medical Sciences ; Vol 2, No 1 (2009)
DOI : 10.2174/1996327000902010025


Hypertension, with a prevalence of up to 30% throughout the world, is increasing in incidence in more affluent and aging populations. Because it is totally asymptomatic, it has been named the "silent killer," as it is the major contributor-or risk factor-to cardiovascular morbidity and mortality. A large body of research over the past several decades has been devoted to investigating the causes and mechanisms of hypertension. Although the causes-genetic and environmental-remain obscure, much progress has been made in elucidating some of the pathogenic mechanisms causing hypertension, as well as its common complications, ie. ischemic heart disease, stroke and renal failure. The ultimate goal of this research is to inhibit these mechanisms and thus prevent or reverse the hypertensive complications.

View article in  :   PDF    


Gavras H, Brown JJ, Lever AF, Macadam RF, Robertson JIS. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971;11:19-22.

Gavras H, Kremer D, Brown JJ, et al. Angiotensin- and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-332.

Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-9.

Gavras H, Brunner HR, Laragh JH. Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Progress in Cardiovascular Disease 1974; 17: 39-49.

Gavras H, Brunner HR, Thurston H, Laragh JH. Reciprocation of rennin dependency with sodium volume dependency in renal hypertension. Science 1975; 188: 1316-7.

Gavras H, Ribeiro A, Gavras I, Brunner HR. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. New Engl J Med 1976; 295: 1278-83.

Gavras H, Waeber B, Kershaw GR, et al. Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. Hypertension 1981; 3: 441-7.

Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Sodium-induced elevation of blood pressure in anephric rats. Science 1980; 209: 935-6.

Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. Am J Physiol 1981; 240: H827- H831.

Gavras H, Hatzinikolaou P, North WG, Bresnahan MR, Gavras I. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension 1982; 4: 400-5.

Gavras H. Possible mechanisms of sodiumdependent hypertension: volume expansion or vasoconstriction? Clin Exp Theory and Practice 1982; A4(4&5): 737-49.

Gavras H, Gavras I. Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens 1989; 7: 601-6.

Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the alpha2a-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999; 33: 14-17.

Makaritsis KP, Johns C, Gavras I, Gavras H. Role of alpha2-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000; 35: 609-13.

Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of Antisense oligodeoxynucleotide targeting of the alpha2e-adrenergic receptor messenger RNA in the central nervous system. Hypertension 2001; 38: 1075-80.

Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Central alpha2Badrenergic receptor antisense in plasmid vector prolongs reversal of salt dependent hypertension. J Hypertens 2003; 21: 961-7.

Brunner HR, Gavras H, Laragh JH, Keenan R. Angiotensin-II blockade in man by sar1 -ala8- angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 11: 1045-8.

Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. JAMA 1977; 238: 880-2.

Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974; 291: 817- 21.

Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan T J. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58: 770-5.

Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-5.

Gavras H. Angiotensin converting enzyme inhibition and its impact on cardiovascular disease. Circulation 1990; 81: 381-8.

Gavras H. Historical evolution of angiotensin II receptor blockers: Therapeutic advantages. J Am Soc Nephrol 1999; 10: S255-S257.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.

Makaritsis KP, Johns C, Gavras I, et al. Sympathoinhibitory function of the alpha2A adrenergic receptor subtype. Hypertension 1999; 34: 403-7.

Gavras I, Manolis AJ, Gavras H. The alpha2 - adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001; 19: 2115-24.

Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA